• OPEN AN ACCOUNT
Indian Indices
Nifty
16,344.55 78.40
(0.48%)
Sensex
54,676.30 349.91
( 0.64%)
Bank Nifty
34,598.60 322.20
( 0.94%)
Nifty IT
29,072.80 283.40
( 0.98%)
Global Indices
Nasdaq
11,354.62 -33.88
(-0.30%)
Dow Jones
31,261.90 8.77
(0.03%)
Hang Seng
20,717.24 596.56
(2.96%)
Nikkei 225
26,739.03 336.19
(1.27%)
Forex
USD-INR
77.39 -0.06
(-0.07%)
EUR-INR
81.54 0.16
(0.20%)
GBP-INR
96.18 0.07
(0.07%)
JPY-INR
0.60 0.00
(0.56%)

EQUITY - MARKET SCREENER

Oil Country Tubular Ltd
Industry :  Steel - Medium / Small
BSE Code
ISIN Demat
Book Value()
500313
INE591A01010
-22.7050576
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
OILCOUNTUB
0
35.79
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

cipla ltd
Cipla receives USFDA final approval for Lanreotide Injection
Dec 20,2021
Cipla announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT®, from Ipsen Biopharmaceuticals Inc. According to IQVIA, SOMATULINE DEPOT® had US sales of approximately $867M for the 12-month period ending October 2021.